EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Repositioning of ezetimibe for the treatment of idiopathic pulmonary fibrosis

Chanho Lee iD, Se Hyun Kwak, Jisu Han, Ju Hye Shin, Byunghun Yoo, Yu Seol Lee, Jeong Su Park, Beom Jin Lim, Jin Gu Lee, Young Sam Kim, Song Yee Kim, Soo Han Bae

European Respiratory Journal · 2024

DOI: 10.1183/13993003.00580-2023 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Respiratory Journal, 2024. Verfasst von Chanho Lee und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, Yonsei University College of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Ezetimibe, Idiopathic Pulmonary Fibrosis, Autophagy, Drug Repositioning. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Korea Health Industry Development Institute, National Research Foundation of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

We previously identified ezetimibe, an inhibitor of Niemann–Pick C1-like intracellular cholesterol transporter 1 and European Medicines Agency-approved lipid-lowering agent, as a potent autophagy activator. However, its efficacy against pulmonary fibrosis has not yet been evaluated. This study aimed to determine whether ezetimibe has therapeutic potential against idiopathic pulmonary fibrosis.

Methods

Primary lung fibroblasts isolated from both humans and mice were employed for mechanistic in vitro experiments. mRNA sequencing of human lung fibroblasts and gene set enrichment analysis were performed to explore the therapeutic mechanism of ezetimibe. A bleomycin-induced pulmonary fibrosis mouse model was used to examine in vivo efficacy of the drug. Tandem fluorescent-tagged microtubule-associated protein 1 light chain 3 transgenic mice were used to measure autophagic flux. Finally, the medical records of patients with idiopathic pulmonary fibrosis from three different hospitals were reviewed retrospectively, and analyses on survival and lung function were conducted to determine the benefits of ezetimibe.

Results

Ezetimibe inhibited myofibroblast differentiation by restoring the mechanistic target of rapamycin complex 1–autophagy axis with fine control of intracellular cholesterol distribution. Serum response factor, a potential autophagic substrate, was identified as a primary downstream effector in this process. Similarly, ezetimibe ameliorated bleomycin-induced pulmonary fibrosis in mice by inhibiting mechanistic target of rapamycin complex 1 activity and increasing autophagic flux, as observed in mouse lung samples. Patients with idiopathic pulmonary fibrosis who regularly used ezetimibe showed decreased rates of all-cause mortality and lung function decline.

Conclusion

Our study presents ezetimibe as a potential novel therapeutic for idiopathic pulmonary fibrosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EzetimibeIdiopathic Pulmonary FibrosisAutophagyDrug RepositioningDisease Models, AnimalAnticholesteremic AgentsAnimalsHumansMiceMaleFemaleMice, TransgenicBleomycinLungFibroblastsRetrospective StudiesAgedMiddle AgedMice, Inbred C57BLMyofibroblastsCholesterol

Substanzen

EzetimibeAnticholesteremic AgentsBleomycinCholesterol

Autor:innen und Institutionen

  • Department of Biomedical Sciences, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • These authors contributed equally to this work.
  • Division of Pulmonology, Allergy and Critical Care Medicine, Department of Internal Medicine, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, Republic of Korea.
  • Department of Biomedical Sciences, Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Department of Pathology, Yonsei University College of Medicine, Seoul, Republic of Korea.

ORCID-Profile: Chanho Lee

Förderung

  • Korea Health Industry Development Institute
  • National Research Foundation of Korea

Zitieren

APA

Lee, C., Kwak, S. H., Han, J., Shin, J. H., Yoo, B., Lee, Y. S., Park, J. S., Lim, B. J., Lee, J. G., Kim, Y. S., Kim, S. Y., & Bae, S. H. (2024). Repositioning of ezetimibe for the treatment of idiopathic pulmonary fibrosis. European Respiratory Journal. https://doi.org/10.1183/13993003.00580-2023

Vancouver

Lee C, Kwak SH, Han J, Shin JH, Yoo B, Lee YS, et al. Repositioning of ezetimibe for the treatment of idiopathic pulmonary fibrosis. European Respiratory Journal. 2024. doi:10.1183/13993003.00580-2023

BibTeX
@article{Lee2024,
  author = {Lee, Chanho and Kwak, Se Hyun and Han, Jisu and Shin, Ju Hye and Yoo, Byunghun and Lee, Yu Seol and Park, Jeong Su and Lim, Beom Jin and Lee, Jin Gu and Kim, Young Sam and Kim, Song Yee and Bae, Soo Han},
  title = {Repositioning of ezetimibe for the treatment of idiopathic pulmonary fibrosis},
  journal = {European Respiratory Journal},
  year = {2024},
  doi = {10.1183/13993003.00580-2023}
}
Kostenlos starten →